Discussing the MOUNTAINEER Phase II Study
Discussing the MOUNTAINEER Phase II study, which resulted in the FDA approval of the Tucatinib and Trastuzumab combination for advanced colorectal cancer HER2 positive patients. In discussion with the lead author, Dr. Tanios S. Bekaii-Saab – Medical Oncology Chief, Leader of Enterprise Wide GI Cancer Program at Mayo Clinic Comprehensive Cancer Center.
